| Ytd | 8.15% | |
| 1y | 67.66% |
| Open | 930.00 | Prev Close | 927.77 | Low | 898.46 | High | 930.47 | Mkt Cap | 56.84B |
| Vol | 363.84K | Avg Vol | 341.33K | EPS | 22.55 | P/E | 40.33 | Forward P/E | 24.62 |
| Beta | -0.03 | Short Ratio | 4.45 | Inst. Own | 47.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-23 | 50-d Avg | 833.57 | 200-d Avg | 816.84 | 1yr Est | 1041.41 |
ARGX News
Live Updates Don't wait: the analyst who called NVIDIA in 2010 just revealed his top 10 AI stocks. S
Argenx SE (NASDAQ:ARGX) stock has faced pressure after the company disclosed changes to the analysis
HC Wainwright sees over $1 billion in sales potential for Argenx's Vyvgart in IMNM despite myosi
HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maint
Argenx stock reversed course Wednesday, bumping above its 21-day line, as investors digested its myo
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and rais
argenx SE (ARGX) Discusses R&D Spotlight on Advancing FcRn Leadership in Autoimmune Myositis Transcr
Executives at argenex NASDAQ: ARGX told investors at a Goldman Sachs healthcare event that they cont
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled i
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment
argenx SE (ARGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The late
argenx NASDAQ: ARGX Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Bl
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain
argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the liv
ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvemen
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology comp
May 27, 2026Amsterdam, the Netherlands - argenx (Euronext and Nasdaq: ARGX), a global immunology com
argenx (ARGX) is building a differentiated autoimmune platform, leveraging VYVGART's commercial succ
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discov
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform a
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Argenx SE – ADR (NASDAQ:ARGX) shares are up during Monday's session as the company celebrates a rece
Argenx shares rise after FDA expands VYVGART approval to all adult gMG patients, widening the drug&#
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult pa
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult pa
Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:ARGX) with a Buy and raises the price ta
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the
argenx SE (ARGX) Q1 2026 Earnings Call Transcript
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.52 per share which beat the analyst consensus
argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the li
Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over
Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers t
Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh
Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintain
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted
RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the pri
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and lowers the
